Work

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2381

Authors: Y-G. Lee, J.S. Ahn, M-J. Ahn, J.H. Kang, R.A. Soo, T. Reungwetwattana, J.C-H. Yang, I. Cicin, D-W. Kim, B. Zaric, H. Go, K.C. Jahng, S. Kim, Y. Lim, K.H. Lee, B.C. Cho

Institutions: Kangbuk Samsung Hospital, Sungkyunkwan University, Samsung Medical Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, National University Hospital, Mahidol University, Ramathibodi Hospital, National Taiwan University Hospital, Trakya University, Seoul National University Hospital, Institute for Pulmonary Diseases of Vojvodina, Yuhan (South Korea), Chungbuk National University Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, Yuhan, Seagen, Daiichi-Sankyo, AstraZeneca Korea, Astellas Pharma, Vifor Pharma, Bayer Korea, Daiichi Sankyo Europe

OpenAlex ID: W4387810728

FWCI:

Cites:

Cited by:

Related to: 10